semaglutide · Novo Nordisk
What should I know about Wegovy?
Wegovy by Novo Nordisk: Weight · heart · MASH. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Start hereWegovy FAQ: Uses, Results, Side Effects, Cost, and CoverageWegovy (semaglutide) is a GLP-1 medicine for weight loss, heart risk, and liver disease, taken as a weekly injection or daily pill. Trials show 13.6% to 14.9% average weight loss; a health-record cohort of semaglutide and tirzepatide users averaged 8.7% at one year.
Common questions
Semaglutide FAQ: Straight Answers to the Most Common QuestionsSemaglutide is a GLP-1 medication sold as Ozempic, Wegovy and Rybelsus, with trial weight loss around 14.9% at 68 weeks. This FAQ covers side effects, prices from $149 self-pay to a $675 list price in 2027, and safety questions including NAION and thyroid warnings.Zepbound Questions Answered: Cost, Doses, Savings, Sleep ApneaZepbound is Eli Lilly's once-weekly tirzepatide injection, approved for weight loss and for moderate-to-severe obstructive sleep apnea in adults with obesity. Without insurance, self-pay prices run $299 to $449 per month, with the $449 price for 7.5 mg and above requiring refills within 45 days.
Side effects
Can You Drink Alcohol on Semaglutide? What Labels and Trials SayThe Ozempic and Wegovy labels list contraindications for MTC/MEN 2 and hypersensitivity, and interactions with insulin and oral drugs. In a 26-week trial, semaglutide cut heavy drinking days by 41.1 vs 26.4 percentage points.Does Semaglutide Cause Muscle Loss?Some of the weight lost on semaglutide is lean tissue, which is true of nearly all weight loss, but the size of that share and what changes it are the parts worth understanding.How to Stop Nausea from Semaglutide: Timing, Diet, and Warning SignsNausea on semaglutide is common, peaks during the first 4 to 5 weeks and during dose escalation, and usually resolves within 8 days. Slower eating, smaller low-fat meals, and small sips of fluid help; a prescriber can slow the dose schedule if needed.Semaglutide and Surgery: Anesthesia Risk and What to Tell Your TeamSemaglutide slows stomach emptying, so food can remain even after fasting. A 2024 multi-society guidance says most patients continue the drug before elective procedures; the FDA label says data are insufficient to recommend stopping, and patients should tell providers about planned procedures.Semaglutide Side Effects: Complete List of Common and Serious ReactionsThe most common semaglutide side effects are digestive: nausea affected 44% of adults on Wegovy 2.4 mg versus 16% on placebo. Serious risks include pancreatitis, gallbladder disease, kidney injury, and a rare eye condition called NAION.Tirzepatide vs Semaglutide Side Effects: What Direct Comparison ShowsSURMOUNT-5 (751 adults) found mostly mild-to-moderate GI side effects in both arms; a 46,620-pair real-world study found an HR of 1.07 for serious GI events with tirzepatide vs semaglutide. Label percentages cannot be compared across drugs.
Stopping and switching
Coming Off Compounded Semaglutide: What to Do When Your Program EndsThe FDA resolved the semaglutide shortage on February 21, 2025, and the shortage-based window that let pharmacies compound copies closed by May 22, 2025. Here is what that means for your program ending and how to move to an FDA-approved drug.Do You Have to Take Wegovy Forever? What the Evidence ShowsWegovy's label sets no stop date and obesity guidance strongly recommends continuing medication during weight maintenance. In withdrawal trials, people who stopped regained most of their lost weight within a year, while those who continued kept it off.GLP-1 Maintenance Dose: What the Research Says About Lowering ItYes, labels allow lower maintenance doses, and a 112-week trial found tirzepatide 5 mg kept weight loss at -16.6% versus -9.9% on placebo. Spacing doses out has weaker evidence: one 30-person case series and computer models.Switching From Wegovy to Zepbound: Doses, Timing, and What to ExpectThere is no official Wegovy-to-Zepbound conversion. The Zepbound label says every patient starts at 2.5 mg weekly for 4 weeks, with no exception for people coming from another GLP-1, and neither label specifies a washout — timing is your prescriber's call.
Compounded
Compounded Semaglutide vs Wegovy: Real Costs and Real TradeoffsCompounded semaglutide can still cost less upfront — one platform lists it starting at $60 plus a membership — but branded Wegovy self-pay is now $349 a month, or $199 for a new patient's first two fills. The gap has narrowed, and the compounded version skips FDA review entirely.How to Spot Counterfeit Ozempic: FDA Lot Numbers and ChecksFDA has named three counterfeit Ozempic 1 mg lots since 2023: NAR0074, PAR0362, and PAR1229. The key check is the EXP/LOT text position on the pen label—above the date and lot is authentic, to the left means do not use it.
Alternatives
Contrave vs. Wegovy: Weight Loss, Safety, Cost, and Who Fits EachContrave produced a placebo-subtracted mean weight loss of 4.7% at one year in its phase 3 trials, while Wegovy produced an average 13.7% loss at 72 weeks in SURMOUNT-5. The two differ sharply in safety profile, dosing, and price.Phentermine vs GLP-1 Drugs: Cost, Weight Loss, and Who Fits WhichPhentermine is a short-term oral appetite suppressant that averaged $15 out of pocket per 30-day fill in 2025, while GLP-1s like Wegovy and Zepbound cost far more — in a 72-week head-to-head trial, Wegovy produced 13.7% and Zepbound 20.2% average weight loss. Here is how they compare.
The GLP-1 market
Do Employers Cover GLP-1 Drugs? What's Happening to Coverage in 2027About 19% of firms with 200 or more workers cover GLP-1s for weight loss, rising to 43% of firms with 5,000+ workers. But surveys show coverage is now peaking: 14% of large employers have dropped weight-loss GLP-1 coverage or plan to in 2027, and no federal law requires it.Does Medicaid Cover Ozempic for Weight Loss? State-by-State 2026Medicaid coverage of Ozempic, Wegovy or Zepbound for weight loss is optional, and only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026. Coverage for diabetes, cardiovascular disease and sleep apnea is required in every state.How Many People Take GLP-1 Drugs in the US? The Numbers by QuarterAbout 11 million unique US patients were on a GLP-1 as of Q2 2025, and the class passed 9 million prescriptions a month by end of 2024. Here is how Wegovy, Zepbound, the Wegovy pill and Foundayo split the market since.The Cheapest Place to Buy Wegovy or Zepbound Right NowAs of 2026 price snapshots, the lowest posted self-pay prices run from $149 a month for oral GLP-1s at Amazon Pharmacy to $299-$449 for Zepbound through LillyDirect, with CVS voucher pricing as low as $149. Verify every price before buying, since several are introductory or time-limited.When Will Ozempic Go Generic? The Real Timeline for SemaglutideOzempic's main US semaglutide patent (US 8,129,343) expires in December 2031, but a thicket of follow-on patents could keep US generic semaglutide off shelves until the late 2030s or beyond. Here is what each date actually means.
Getting started
Do I Qualify for Wegovy, Zepbound or Another GLP-1, and Who Decides?There is no application and no official qualification body. Three separate gates decide access: the FDA label, a prescriber's judgment, and your insurance plan. The weight-loss labels cover adults with obesity, or overweight plus at least one weight-related condition — and print no BMI number.How to Find an Obesity Medicine Doctor Near MeYou do not always need a specialist to get a weight-loss drug, but the OMA member directory lists obesity medicine clinicians by city, state, or ZIP, and the ABOM Diplomate Search verifies board certification, which requires at least 60 hours of obesity-specific education plus an exam.How to Get a GLP-1 Prescription: Every Legitimate RouteWegovy, Zepbound and other GLP-1s require a prescription from a clinician who treats obesity — primary care doctor, NP, PA, specialist or telehealth prescriber. Here is what each route costs, from NovoCare self-pay at $149 to the Medicare GLP-1 Bridge at $50 per month.Questions to Ask Your Doctor About GLP-1 Medication Before StartingBring a written list to your GLP-1 appointment covering the approved use, eligibility, safety screening, drug interactions, pregnancy planning, dosing, follow-up, and cost. The questions come from FDA prescribing labels and ADA 2026 care standards, so every answer is checkable.What to Expect in Your First Month on a GLP-1 MedicationThe first month on Zepbound, Wegovy, Ozempic, or the new GLP-1 pills is a titration phase, not a results phase. Zepbound starts at 2.5 mg weekly and Wegovy at 0.25 mg weekly, each held for 4 weeks before any increase, per the FDA labels.Which GLP-1 Is Right for Me? How Doctors Actually DecideThere is no single best GLP-1. Doctors match the drug to the indication you meet, the format you can keep up with, dose ceilings, side effects, and your other medicines — the ADA says to individualize treatment, and even a 5–7% weight loss improves glycemia.
Cost
Does Insurance Cover Wegovy? How to Check and Appeal a DenialCoverage depends on your plan: 67% of large employers cover GLP-1s for weight management, but only 13 state Medicaid programs do, and 26 of 300 ACA carriers. Most plans require prior authorization, and denials can be appealed.Does Medicare Cover Wegovy or Ozempic? What You'll Actually PayMedicare still cannot cover Wegovy or Ozempic for weight loss, but the Medicare GLP-1 Bridge offers a $50 monthly copay on certain GLP-1s from July 1, 2026 through December 31, 2027. Ozempic is not on the Bridge drug list, though Part D plans can cover it for diabetes.How Much Does Semaglutide Cost Without Insurance in 2026?Without insurance, brand-name semaglutide now runs about $149 to $499 a month depending on which product and dose you take, far below the $1,027 to $1,349 list prices.Ozempic Savings Card and Coupons: Which One You Qualify ForThe Ozempic "coupon" is really three programs: a $25/month copay card for commercially insured patients (capped at $100 in savings), a $199–$499/month self-pay price, and a free-medicine Patient Assistance Program for uninsured low-income patients. Which one applies depends on your insurance.The Cheapest Way to Get Semaglutide: Every Legal Route and PriceThe cheapest legal route is Novo Nordisk's Patient Assistance Program, which supplies medicine free to approved applicants with Medicare or no insurance. Medicare's GLP-1 Bridge runs $50 a month. With commercial insurance, the savings offer is $25 a month for up to 3 months; cash prices start at $149.
Drug pipeline
Eli Lilly vs Novo Nordisk: Who's Winning the Weight-Loss Drug Race?Eli Lilly leads the US GLP-1 market with about 57% of prescriptions to Novo Nordisk's 37%, but Novo's Wegovy pill leads the pill race with about 183K weekly prescriptions to Foundayo's 47.5K, per IQVIA estimates cited by analysts. Starting prices have fallen from about $1,000 to $149–$299 per month.New Weight Loss Drugs Coming Out: Ranked by FDA Approval StatusCagriSema is the only new weight-loss drug actually under FDA review, filed December 18, 2025, with review expected in 2026. Retatrutide is next, with a filing planned for Q1 2027, and survodutide has Phase 3 data but no US filing yet.Orforglipron (Foundayo): How the GLP-1 Pill Works, Costs, and ComparesOrforglipron, sold as Foundayo, is Eli Lilly's once-daily GLP-1 weight-loss pill approved by the FDA on April 1, 2026. In its main trial, people on the highest dose lost 12.4% of body weight (27.3 lbs); self-pay runs about $149–$349 per month.Survodutide: Weight Loss Results, Side Effects, and Approval StatusSurvodutide is an investigational once-weekly glucagon/GLP-1 injection from Boehringer Ingelheim. In the Phase 3 SYNCHRONIZE-1 trial it produced up to 16.6% weight loss versus 3.2% for placebo, but it is not FDA-approved and cannot be prescribed yet.When Will Generic Ozempic Be Available in the US?No FDA-approved generic Ozempic exists as of August 2026, and experts do not expect one in the US until at least the end of 2031. India and Canada already have approved generics; the advocacy group I-MAK projects US patents could block entry as far out as 2042.
Results
Exercise on GLP-1 Drugs: What the Evidence Actually ShowsGLP-1 drugs produce major weight loss without supervised exercise, but roughly 25-39% of the weight lost is lean mass, versus 17.5% when lifestyle programs include resistance training. Exercise's clearest benefits show up in body composition and keeping weight off after the drug stops.GLP-1 Plateau: Why Weight Loss Stalls on Wegovy and ZepboundYes — a stall is a normal part of treatment. In tirzepatide trials, the median time to a weight plateau was 24.3 to 36.1 weeks depending on starting BMI, and about 90% of participants had plateaued by week 72.How Fast Does Semaglutide Work? Trial Results by WeekSemaglutide weight-loss results come from fixed trial checkpoints: an average -10.6% at week 20, -14.9% at week 68, and a plateau near week 60. The 2.4 mg dose is reached at week 16, and appetite effects were measured at week 20, with lunch intake 35% lower than placebo.How Fast Does Zepbound Work? Timeline of Weight Loss ResultsZepbound's biggest share of loss came in the first 24 weeks — about 13.3% to 14.5% among adherent trial participants who lost at least 5% — with a plateau typically at 24 to 36 weeks and 72-week label averages of 15.0% to 20.9% depending on dose.How Much Protein on a GLP-1: What Published Targets SayPublished sources suggest roughly 1.0–1.5 g of protein per kg of body weight per day, or 80–120 g total, for adults losing weight on semaglutide or tirzepatide, with about 20–30 g per meal plus resistance training to help preserve muscle.Living on a GLP-1: Daily Life With Wegovy or ZepboundLiving on a GLP-1 is mostly a weekly rhythm: one shot, a fridge, and paperwork. The labels answer missed doses and travel storage (Wegovy single-dose pens last 28 days out of the fridge, Zepbound 21 days), while surveys show 32.4% work impairment at treatment start and stigma toward Ozempic users.
FDA and regulation
FDA Approval History of Semaglutide: Every Date, ExplainedSemaglutide was first approved as Ozempic on December 5, 2017, followed by Rybelsus (September 20, 2019), Wegovy (June 4, 2021), Wegovy tablets (December 22, 2025) and Wegovy HD (March 19, 2026). Here is each approval, use, and how to verify the dates yourself.Is Semaglutide Still in Shortage? FDA Status for 2026No. FDA declared the semaglutide injection shortage resolved on February 21, 2025, and an FDA statement dated April 1, 2026 confirms Ozempic and Wegovy are off the drug shortage list. Local pharmacy stock-outs can still happen.Semaglutide Approvals by Country: Where Ozempic and Wegovy Are ApprovedOzempic is approved in the US, EU, UK, Canada, Australia, Japan and China; Wegovy also in India and the UAE. Approved uses and dates differ by market. Canada approved the first G7 generic semaglutide on 28 April 2026 after a patent lapsed over an unpaid CAD 250 fee; US exclusivity runs to 2032.
Foundayo
Who they're for
GLP-1 After Bariatric Surgery: Does It Work for Weight Regain?Yes — the evidence says it can work. In a 68-week randomized trial, semaglutide 2.4 mg once weekly produced −18.0% body weight versus +0.4% on placebo in people with poor results after gastric bypass or sleeve, with no new safety concerns. No GLP-1 is FDA-approved specifically for post-bariatric use.GLP-1 and Men's Health: Testosterone, Erections, Sperm and MusclePost hoc analyses reported in a conference abstract suggest women lose about 40% more weight than men on GLP-1 drugs. A review of five trials found no negative impact on hormones, sexual function or sperm quality, with possible testosterone gains for men whose low T is driven by obesity [1][10].GLP-1 and Menopause: Weight Loss Evidence and Hormone Therapy EffectsGLP-1 drugs still produce strong weight loss after menopause: tirzepatide cut body weight 23% vs 3% placebo in postmenopausal women, and the STEP pool showed a median −16.4% for semaglutide. Hormone therapy is linked to more loss (16% vs 12% at 12 months), but no trial proves it causes the difference.GLP-1 for Teens: Which Drugs Are Approved and What Studies ShowOnly Wegovy injection (ages 12+) and Saxenda (ages 12+ with body weight over 60 kg) carry a teen weight-loss indication. Mounjaro is labeled for ages 10 and older only for type 2 diabetes, not weight loss. Zepbound is adults-only.GLP-1 for Type 1 Diabetes: What the Research Actually ShowsNo GLP-1 drug is FDA-approved for type 1 diabetes. One small randomized trial found 36% of adults on semaglutide hit a combined glucose-and-weight goal versus 0% on placebo, with weight 8.8 kg lower than placebo at 26 weeks.GLP-1 Over 65: What the Labels, Trials and Medicare Rules ShowNo GLP-1 label sets an upper age limit, and pooled trials find efficacy and safety in adults 65 and older broadly comparable to younger adults, though side effects force stopping more often after 65. Medicare's GLP-1 Bridge covers certain drugs for $50 a month from July 1, 2026 through December 31, 2027.Who Should Not Take GLP-1 Drugs: Contraindications and WarningsOnly two things rule out these drugs outright: a personal or family history of medullary thyroid carcinoma or MEN 2, and hypersensitivity to the drug or its ingredients (Wegovy's label says "known" hypersensitivity; the other three say "serious"). Everything else is a warning or "not recommended."
News timeline
GLP-1 News 2025: Stories That Changed Prices, Access and ApprovalsIn 2025, the FDA ended the semaglutide shortage, cash prices fell from a $1,349 list price to $499, Medicare obesity coverage and a $245 government price were set for 2026, and semaglutide gained kidney, liver and oral weight-loss approvals.GLP-1 News 2026: Pills, Price Cuts and the Novo Stock Drop2026 brought the first GLP-1 weight-loss pills (Wegovy pill from $149/month cash, Foundayo approved April 1), TrumpRx discounts to about $350, a $675 list price coming January 1, 2027, and a 16% Novo stock drop. Here is what each change means for what you pay.History of Ozempic and Semaglutide: Year-by-Year Timeline of ApprovalsOzempic was FDA approved on December 5, 2017 for type 2 diabetes, followed by Rybelsus (September 20, 2019), Wegovy (June 4, 2021) and the Wegovy pill (December 22, 2025). Here is the full year-by-year history of semaglutide.What's Next for GLP-1 Drugs: Approvals, Prices and Deadlines to WatchThe FDA is anticipated to decide on CagriSema by late 2026, Lilly aims to file retatrutide in Q1 2027, and Wegovy and Ozempic list prices drop to $675 per month on January 1, 2027. Here are the key dates on the calendar.
Insurance
GLP-1 Prior Authorization Requirements: What Insurers Ask ForInsurers approving Wegovy or Zepbound typically require a BMI of 30 or higher (27 with a comorbidity), documented participation in a weight management program, and proof of at least 5% weight loss at renewal. Exact rules vary by plan and change often.How to Appeal a Zepbound Denial: Steps, Deadlines, and Your OddsIf your insurer denied Zepbound or another GLP-1, appeal through the plan first, then external review — a written request within 4 months. Among Medicare Advantage denials appealed in 2024, 80.7% were overturned, though only 11.5% were appealed at all.How to Get Wegovy Covered by Insurance (and What to Do If It Says No)Coverage for Wegovy and Zepbound is decided by your plan's formulary and prior-authorization rules, not your prescriber. In 2026, 7% of commercially insured people — nearly 13 million — have no coverage for any weight-loss GLP-1, and 88% of those with coverage face added requirements.Is Wegovy HSA Eligible? Paying for GLP-1 Drugs With HSA or FSA FundsYes. Wegovy, Zepbound, Ozempic and other GLP-1s can be paid from an HSA or FSA when prescribed to treat a physician-diagnosed disease such as obesity or diabetes. The 2026 HSA limit is $4,400 self-only and $8,750 family; the FSA limit is $3,400.Medicaid GLP-1 Coverage by State in 2026Thirteen state Medicaid programs covered GLP-1s for obesity as of January 2026, down from 16 in October 2025. Every state still covers them for type 2 diabetes, and Massachusetts and Rhode Island are the latest states moving to drop weight-loss coverage.Medicare GLP-1 Bridge Program Eligibility and CostsThe Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 and gives eligible Part D beneficiaries certain GLP-1 weight-loss drugs for a $50 copay per monthly fill. Eligibility requires age 18 or older, an eligible Part D plan type, and BMI criteria met when GLP-1 therapy started.Novo Nordisk Patient Assistance Program: Wegovy and Lilly CaresFree GLP-1 medicine through a manufacturer program is real but narrow. Novo Nordisk's PAP gives free medicine only to Medicare or uninsured patients under income limits of 200%–400% of the federal poverty level, while Lilly Cares' current lists include Trulicity but not Zepbound or Mounjaro.Which Employers Cover GLP-1s for Weight Loss?No public list names the employers that cover Wegovy or Zepbound, but surveys show coverage ranges from nearly one-fifth of firms with more than 200 workers to 67% of large Business Group on Health members, and a growing share of employers are dropping or restricting coverage heading into 2027. Here is what the data show and how to check your own plan.
How it works
How Does Semaglutide Work in the Body?Semaglutide is a lab-made copy of the gut hormone GLP-1 that binds GLP-1 receptors to stimulate insulin, lower glucagon, slow stomach emptying, and reduce appetite in the brain. Three chemical changes give it a half-life of about one week, so one injection lasts seven days.How Does Zepbound Work? GIP and GLP-1, Explained SimplyZepbound (tirzepatide) activates two gut-hormone receptors at once, GIP and GLP-1, which is why it is called a dual agonist. It starts at 2.5 mg once weekly for 4 weeks and can go up to a 15 mg weekly maintenance dose.How Long Does Semaglutide Stay in Your System?Semaglutide has an elimination half-life of approximately 1 week, so it remains in circulation about 5 weeks after the last Ozempic dose and 5 to 7 weeks after the last Wegovy 2.4 mg dose. Here is what that means for starting, stopping, pregnancy planning, and surgery.Oral Semaglutide vs Injection: Pills, Pens, and What Actually DiffersOral semaglutide (Rybelsus, Ozempic, Wegovy tablets) and injectable semaglutide (Ozempic, Wegovy) are the same molecule with different rules: pills are daily on an empty stomach with a 30-minute wait; shots are weekly with no food limits. OASIS 4: the 25 mg pill gave −13.6% weight loss vs −2.2% placebo.Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide (Mounjaro) targets two. In the only head-to-head trial, tirzepatide produced −20.2% body weight vs −13.7% for semaglutide at 72 weeks.Who Discovered GLP-1? The People Behind Ozempic and WegovyNo single person discovered GLP-1. The work spans more than 30 years across several labs, and the 2024 Lasker Prize went to Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen. Ozempic is not made from Gila monster venom — that was exenatide, approved in 2005.
How to use
How Long Can Ozempic Be Out of the Fridge? GLP-1 Storage RulesAn Ozempic pen can stay out of the fridge for 56 days after first use at 59°F to 86°F. Zepbound and Mounjaro single-dose pens get 21 cumulative days, and their multi-dose vials and KwikPens get 30 days. All of them must be thrown away if frozen.How to Inject Wegovy: Devices, Sites, and What the Label SaysWegovy is injected once weekly under the skin of the abdomen, thigh, or upper arm; usual maintenance is 2.4 mg once weekly. Exact steps depend on your device — single-dose pen, single-dose syringe, or FlexTouch pen — and each device has its own Instructions for Use.How to Take GLP-1 Pills Correctly: Wegovy Tablets vs. FoundayoOral semaglutide (Wegovy tablets) is taken once daily on an empty stomach in the morning with up to 4 ounces of water, then wait at least 30 minutes before food, drink, or other medicines. Foundayo is one tablet a day, any time, with or without food.How to Use a Wegovy Savings Card at the Pharmacy: Codes and NDCsShow the Wegovy savings card to your pharmacist at pickup; it carries BIN, PCN, GRP and ID numbers that route the claim to SS&C Health with the right other coverage code (08, 03, or 00/01), and claims must be submitted within 180 days of the fill date.Missed Dose of Ozempic or Another GLP-1: What the Labels SayEach GLP-1 product has its own missed-dose rule. The Ozempic label allows the shot within 5 days of the missed dose; Wegovy injection depends on whether the next dose is more or less than 2 days (48 hours) away; Mounjaro and Zepbound allow 4 days (96 hours).
Trial evidence
How Much Weight Do You Lose on Semaglutide? Results by Dose and TypeIn the STEP 1 trial, adults taking 2.4 mg semaglutide weekly lost an average of 14.9% of body weight (15.3 kg, about 34 lb) over 68 weeks, versus 2.4% on placebo. Results vary by dose, pill versus injection, and the population studied.How Much Weight Do You Lose on Zepbound? Trial Results by DoseIn the main 72-week trial, adults without diabetes lost an average of 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg of Zepbound, versus 3.1% on placebo. Losses ran smaller with type 2 diabetes and in real-world data.SELECT Trial Semaglutide Explained: Heart Attack and Stroke ResultsSELECT tested 2.4 mg weekly semaglutide against placebo in 17,604 adults with overweight or obesity and existing heart disease but no diabetes. It cut major cardiovascular events 20% relative — 6.5% vs 8.0% — over about 3.3 years.Semaglutide vs Tirzepatide: Which Is Better for Weight Loss? SURMOUNT-5 ExplainedIn the first published head-to-head randomized trial in adults with obesity without diabetes, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. Here is what the study showed, plus side effects, heart evidence, and how clinicians say to choose.What Happens When You Stop Taking Semaglutide (Ozempic, Wegovy)Yes — across randomized trials, people who stopped semaglutide or tirzepatide regained an average of 9.69 kg, and in one tirzepatide withdrawal trial the group switched to placebo regained 14.0% of body weight in a year.
Medications
How to Store an Ozempic Pen, Inject It, and Throw It Away SafelyUnused Wegovy pens stay in the fridge at 36 °F to 46 °F and can sit out at 46 °F to 86 °F for up to 28 days before the cap comes off. Ozempic storage limits are in section 16 of its prescribing information. Inject once weekly into the abdomen, thigh, or upper arm, and throw used pens in a sharps container.List of GLP-1 Medications: Every FDA-Approved Drug in 2026Nine GLP-1 brands are FDA-approved and sold in the US in 2026: Wegovy, Zepbound, Foundayo, Saxenda, Ozempic, Rybelsus, Mounjaro, Trulicity and Victoza. Byetta and Bydureon BCise were discontinued in 2024, CagriSema is under review, and the US semaglutide compound patent expires December 5, 2031.Ozempic vs Wegovy vs Rybelsus: What Actually DiffersOzempic, Wegovy and Rybelsus all contain semaglutide, but they differ in approved uses, doses, shot vs pill, and price. The reformulated Rybelsus tablets were renamed Ozempic tablets on January 30, 2026, and the Rybelsus name is being retired in the US as the Ozempic pill rolls out from May 4, 2026.Wegovy Pill: What It Is, How Well It Works, and What It CostsThe FDA approved the Wegovy pill (oral semaglutide) on December 22, 2025, the first oral GLP-1 for obesity in the US. In OASIS 4, people lost about 17% of body weight at 64 weeks if all stayed on treatment (about 14% regardless of adherence) vs about 3% on placebo; self-pay starts at $149 per month.Wegovy vs Zepbound: Weight Loss, Cost, Devices and Side EffectsWegovy (semaglutide) and Zepbound (tirzepatide) are both weekly injections for weight loss. In the one head-to-head trial, Zepbound produced 20.2% average weight loss versus 13.7% for Wegovy, though that study was open-label. Approved uses, devices and self-pay costs differ.
GLP-1 culture
The drugmakers
Novo Nordisk Pipeline: What Comes After Wegovy in 2026 and BeyondNovo Nordisk's pipeline after Wegovy already includes two 2026 launches: the Wegovy pill and Wegovy HD (7.2 mg). Next up is CagriSema, with an FDA decision expected in Q4 2026, followed by zenagamtide in phase 3. Semaglutide's US patent protection runs to 2032.Who Makes Ozempic? Novo Nordisk, ExplainedOzempic is made by Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark, run by president and CEO Maziar Mike Doustdar. The company reported DKK 309,064 million in 2025 net sales and is controlled by the Novo Nordisk Foundation through Novo Holdings.
Liraglutide
Saxenda vs Wegovy: Which Works Better and How They DifferIn the 68-week STEP 8 trial, weekly semaglutide 2.4 mg produced −15.8% mean weight loss vs −6.4% for daily liraglutide 3.0 mg — a 9.4-point gap. Generic liraglutide launched in August 2025; a GoodRx coupon listed $372.45 for one 5-pen carton (ZIP 33102, September 14, 2026).Switching From Liraglutide to Semaglutide or Zepbound: Doses and GapsNone of the Wegovy, Zepbound, oral semaglutide, or Saxenda labels offers a liraglutide-to-weekly-drug conversion. Wegovy starts at 0.25 mg once weekly for 4 weeks and Zepbound at 2.5 mg once weekly for 4 weeks, and no washout period appears in these labels.
Emerging uses
Recent Wegovy news
Full timeline- Research and trials
Vanda's tradipitant cut Wegovy-induced vomiting by 27% in Phase 3 trial
- Research and trials
Novo reports liver fat fell sharply in 55-person Wegovy sub-study